Melanotan 2

GOALS TREATED:
Muscle Gain

 

Fat Loss
Injury Rehabilitation  
Anti-ageing  
Libido
Tanning
What is Melanotan II – MT2?

Melanotan II (MT2)

Overview

Melanotan II (MT2) is a synthetic analogue of the alpha-melanocyte-stimulating hormone (α-MSH), initially developed to stimulate melanin production and provide a therapeutic tan, thereby reducing UV exposure and lowering skin cancer risk. Melanotan II is especially valuable for individuals with fair skin types prone to sunburn. Beyond tanning, it has shown effects on appetite suppression, weight management, and sexual arousal.

Key Benefits of Melanotan II

  • Tanning and UV Protection: Promotes melanin production in the skin, resulting in a deeper tan with reduced sun exposure, lowering the risk of UV damage and skin cancer.
  • Skin Health: Prolongs tan retention, supports natural melanin production, and minimizes the sun's adverse effects, such as premature aging and skin damage.
  • Sexual Health: Stimulates libido and sexual arousal, with noticeable effects on sexual function in both men and women.
  • Weight Management: Reduces appetite and aids in fat oxidation, contributing to lean muscle maintenance.
  • Neuroprotection: Potential therapeutic benefits in Alzheimer’s and autism through enhanced neuroprotection, behavior regulation, and mood improvement.

Mechanism of Action

Melanotan II binds to melanocortin receptors, primarily MC-1R and MC-4R. MC-1R stimulation on melanocytes increases melanin production, enhancing pigmentation and providing a protective tan. Binding to MC-4R in the brain is associated with increased sexual arousal, appetite suppression, and energy regulation.

Clinical Research and Applications

Skin Cancer Prevention and Tanning

Studies show Melanotan II can induce melanin production with minimal UV exposure, suggesting it as a preventive measure against skin cancer. Tanning achieved through MT2 is prolonged, providing a photoprotective effect against UV radiation.

Sexual Arousal and Erectile Dysfunction

MT2 has been investigated as a treatment for erectile dysfunction and hypoactive sexual desire, with studies showing it significantly enhances sexual arousal and function. Clinical trials have shown MT2's potential in treating both male and female sexual dysfunction.

Weight and Appetite Regulation

Research reveals MT2 influences appetite suppression and reduces preference for high-fat foods through MC-4R pathways, potentially aiding in weight management and obesity treatment.

Side Effects and Considerations

Common short-term side effects include mild nausea, facial flushing, and appetite loss. Increased libido and darker moles or freckles have also been noted. Some individuals may experience spontaneous erections within a few hours post-administration. Long-term side effects require more study, as there are reports linking MT2 with potential risks of melanoma and pigmentation changes in high dosages.

Product Information

  • Molecular Formula: C50H69N15O9
  • Molecular Weight: 1024.198 g/mol
  • Peptide Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2

Storage: Store frozen until first use; then refrigerate at 2°C - 8°C for up to 56 days.

References:
  1. Ultraviolet (UV) Radiation, American Cancer Society. https://www.cancer.org/cancer/cancer-causes/radiation-exposure/uv-radiation.html
  2. Ryakhovsky, Vladimir V et al. “The first preparative solution phase synthesis of melanotan II.” Beilstein journal of organic chemistry vol. 4 (2008): 39. doi:10.3762/bjoc.4.39. https://pubmed.ncbi.nlm.nih.gov/19043625/
  3. Mac E. Hadley, Discovery that a melanocortin regulates sexual functions in male and female humans, Peptides, Volume 26, Issue 10, 2005, Pages 1687-1689, ISSN 0196-9781, https://doi.org/10.1016/j.peptides.2005.01.023
  4. King, Stephen H et al. “Melanocortin receptors, melanotropic peptides and penile erection.” Current topics in medicinal chemistry vol. 7,11 (2007): 1098-1106. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694735/
  5. Peters, Björn et al. “Melanotan II: a possible cause of renal infarction: review of the literature and case report.” CEN case reports vol. 9,2 (2020): 159-161. doi:10.1007/s13730-020-00447-z. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148395/
  6. Melanotan, Vitamin and Supplements. https://www.webmd.com/vitamins/ai/ingredientmono-884/melanotan
  7. Lan, E L et al. “Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide.” Journal of pharmaceutical sciences vol. 83,8 (1994): 1081-4. doi:10.1002/jps.2600830805. https://pubmed.ncbi.nlm.nih.gov/7983590/
  8. Ter Laak, Mariël P et al. “The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat.” European journal of pharmacology vol. 462,1-3 (2003): 179-83. doi:10.1016/s0014-2999(02)02945-x. https://pubmed.ncbi.nlm.nih.gov/12591111/
  9. Wessells, H et al. “Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.” International journal of impotence research vol. 12 Suppl 4 (2000): S74-9. doi:10.1038/sj.ijir.3900582. https://pubmed.ncbi.nlm.nih.gov/11035391/
  10. Hjuler, Kasper Fjellhaugen, and Henrik Frank Lorentzen. “Melanoma associated with the use of melanotan-II.” Dermatology (Basel, Switzerland) vol. 228,1 (2014): 34-6. doi:10.1159/000356389. https://pubmed.ncbi.nlm.nih.gov/24355990/
  11. Peters B, Hadimeri H, Wahlberg R, Afghahi H. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep. 2020 May;9(2):159-161. doi: 10.1007/s13730-020-00447-z. Epub 2020 Jan 18. PMID: 31953620; PMCID: PMC7148395. https://pubmed.ncbi.nlm.nih.gov/31953620/
  12. John Devlin, Adam Pomerleau, Jenelle Foote. (2013) Melanotan II overdose associated with priapism. Clinical Toxicology 51:4, pages 383-383. https://www.tandfonline.com/doi/full/10.3109/15563650.2012.740637
  13. Nelson, Michael E et al. “Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.” Clinical toxicology (Philadelphia, Pa.) vol. 50,10 (2012): 1169-73. doi:10.3109/15563650.2012.740637. https://pubmed.ncbi.nlm.nih.gov/23121206/
  14. Drug Profile: Melanotan II https://adisinsight.springer.com/drugs/800010143
  15. FDA warns against using Melanotan II https://www.upi.com/Science_News/2007/09/05/FDA-warns-against-using-Melanotan-II/44981189007945/
  16. Breindahl, Torben et al. “Identification and characterization by LC-UV-MS/MS of Melanotan II skin-tanning products sold illegally on the Internet.” Drug testing and analysis vol. 7,2 (2015): 164-72. doi:10.1002/dta.1655. https://pubmed.ncbi.nlm.nih.gov/24771717/